These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 23697926)
1. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926 [TBL] [Abstract][Full Text] [Related]
2. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591 [TBL] [Abstract][Full Text] [Related]
4. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858 [TBL] [Abstract][Full Text] [Related]
5. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Brouwers A; Verel I; Van Eerd J; Visser G; Steffens M; Oosterwijk E; Corstens F; Oyen W; Van Dongen G; Boerman O Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595 [TBL] [Abstract][Full Text] [Related]
6. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724 [TBL] [Abstract][Full Text] [Related]
10. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657 [TBL] [Abstract][Full Text] [Related]
11. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule. Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612 [TBL] [Abstract][Full Text] [Related]
12. Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. Garousi J; Honarvar H; Andersson KG; Mitran B; Orlova A; Buijs J; Löfblom J; Frejd FY; Tolmachev V Mol Pharm; 2016 Nov; 13(11):3676-3687. PubMed ID: 27529191 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961 [TBL] [Abstract][Full Text] [Related]
14. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. Zhu W; Li X; Zheng G; Bai C; Ji Z; Zhang H; Xing H; Zhang Y; Huo L Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3116-3125. PubMed ID: 37246998 [TBL] [Abstract][Full Text] [Related]
15. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812 [TBL] [Abstract][Full Text] [Related]
17. A CAIX Dual-Targeting Small-Molecule Probe for Noninvasive Imaging of ccRCC. He C; Liu F; Tao J; Wang Z; Liu J; Liu S; Xu X; Li L; Wang F; Yang X; Zhu H; Yang Z Mol Pharm; 2024 Jul; 21(7):3383-3394. PubMed ID: 38831541 [TBL] [Abstract][Full Text] [Related]
18. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091 [TBL] [Abstract][Full Text] [Related]
19. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Minn I; Koo SM; Lee HS; Brummet M; Rowe SP; Gorin MA; Sysa-Shah P; Lewis WD; Ahn HH; Wang Y; Banerjee SR; Mease RC; Nimmagadda S; Allaf ME; Pomper MG; Yang X Oncotarget; 2016 Aug; 7(35):56471-56479. PubMed ID: 27437764 [TBL] [Abstract][Full Text] [Related]
20. Targeting CAIX with [ Yang X; Zhu H; Yang X; Li N; Huang H; Liu T; Guo X; Xu X; Xia L; Deng C; Tian X; Yang Z Mol Pharm; 2019 Apr; 16(4):1532-1540. PubMed ID: 30803240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]